Planta Med 2019; 85(18): 1452
DOI: 10.1055/s-0039-3399804
Main Congress Poster
Poster Session 1
© Georg Thieme Verlag KG Stuttgart · New York

Use of Botrytis cinerea enzymatic secretome to generate original phenylpropanoids derivatives having Wnt inhibition on triple negative breast cancer cells

D Righi
1   School of Pharmaceutical Sciences, EPGL, University of Geneva, University of Lausanne,, CMU, 1, Rue Michel Servet, 1211 Geneva 4, Switzerland
,
R Hubert
1   School of Pharmaceutical Sciences, EPGL, University of Geneva, University of Lausanne,, CMU, 1, Rue Michel Servet, 1211 Geneva 4, Switzerland
,
A Koval
2   University of Geneva,, Department of Cell Physiology and Metabolism, Translational Research Centre in Oncohaematology, Faculty of Medicine, Geneva, Switzerland
,
S Schnee
3   Agroscope, Research Division of Plant Protection,, Route de Duillier 50, P.O. Box 1012, 1260 Nyon, Switzerland
,
L Marcourt
1   School of Pharmaceutical Sciences, EPGL, University of Geneva, University of Lausanne,, CMU, 1, Rue Michel Servet, 1211 Geneva 4, Switzerland
,
E Michellod
3   Agroscope, Research Division of Plant Protection,, Route de Duillier 50, P.O. Box 1012, 1260 Nyon, Switzerland
,
R Perozzo
1   School of Pharmaceutical Sciences, EPGL, University of Geneva, University of Lausanne,, CMU, 1, Rue Michel Servet, 1211 Geneva 4, Switzerland
,
VL Katanaev
2   University of Geneva,, Department of Cell Physiology and Metabolism, Translational Research Centre in Oncohaematology, Faculty of Medicine, Geneva, Switzerland
,
J-L Wolfender
1   School of Pharmaceutical Sciences, EPGL, University of Geneva, University of Lausanne,, CMU, 1, Rue Michel Servet, 1211 Geneva 4, Switzerland
,
K Gindro
2   University of Geneva,, Department of Cell Physiology and Metabolism, Translational Research Centre in Oncohaematology, Faculty of Medicine, Geneva, Switzerland
,
EF Queiroz
1   School of Pharmaceutical Sciences, EPGL, University of Geneva, University of Lausanne,, CMU, 1, Rue Michel Servet, 1211 Geneva 4, Switzerland
› Author Affiliations
Further Information

Publication History

Publication Date:
20 December 2019 (online)

Also available at
 

The biotransformation of natural products using the Botrytis cinerea enzymatic secretome has proven to be an innovative and effective way to produce original derivatives [1]. Such reactions produce very complex compounds from simple natural product scaffolds, some of which have interesting biological activities. In the present work, the biotransformation of two 4-hydroxy-cinnamic acid derivatives was investigated. Caffeic acid and ferulic acid were successively incubated with the crude enzymatic extract (secretome) of B. cinerea. These biotransformations, were first carried out at the analytical scale for 24 hours. They were monitored by UHPLC-high resolution mass spectrometry (HRMS) to verify the complete transformation of starting substrates and the production of related derivatives. The reactions were then scaled-up with 200 mg of the starting compounds, controlled by HPLC-PDA-ELSD and purified by high-resolution semi-preparative HPLC. The same selectivity and a precise prediction of the separation between the analytical and semi-preparative scale were obtained using geometrical chromatography transfer methods [2]. The isolated compounds were fully characterized by NMR and HRMS. Using this approach eleven dimeric or trimeric phenylpropanoids analogues were obtained. Among these compounds, three are described here for the first time and some of them presented Wnt inhibition activities in breast cancer cells.

Zoom Image
Fig.1
 

  • References

  • 1 Gindro K, Schnee S, Righi D, Marcourt L, Nejad Ebrahimi S, Codina JM, Voinesco F, Michellod E, Wolfender J-L, Queiroz EF. . Generation of antifungal stilbenes using the enzymatic secretome of Botrytis cinerea . J Nat Prod 2017; 80: 887-898.
    CrossrefPubMedGoogle Scholar
  • 2 Guillarme D, Nguyen DT, Rudaz S, Veuthey JL. Method transfer for fast liquid chromatography in pharmaceutical analysis: application to short columns packed with small particle. Part II: gradient experiments. Eur. J Pharm Biopharm 2008; 68 (02) : 430-40.
    PubMedGoogle Scholar